GVR Report cover Biomarker Testing Services Market Size, Share & Trends Report

Biomarker Testing Services Market Size, Share & Trends Analysis Report By Services (Biomarker Assay Development & Validation, Flow Cytometry), By End-user (Research Institutes, CROS), By Region, And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-4-68039-986-1
  • Number of Pages: 100
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2020
  • Industry: Healthcare

Report Overview

The global biomarker testing services market size was valued at USD 759.6 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 6.9% from 2022 to 2030. Growing demand for biomarkers in diagnosis; awareness about biomarkers among researchers, and high demand for outsourcing biomarker testing services among the pharmaceutical and biopharmaceutical companies are some of the key drivers supporting the market growth.  During the pandemic, the majority of studies were conducted for COVID-19. Clinical studies on COVID-19 therapeutics are still being conducted, as there is a growing need to find a safe and effective treatment for all the new variants of the virus. The increasing research is expected to improve drug discovery activities, which will require biomarkers for analysis. This is expected to support the market in the post-pandemic period.

U.S. biomarker testing services market size, by services, 2020 - 2030 (USD Million)

R&D is leading to the discovery of novel biomarkers. For instance, in 2020, sTNFR2 was revealed as a novel biomarker for the diagnosis of acute adult T-cell leukemia/lymphoma. Similarly, in 2018, FDA qualified Plasmodium 18S rRNA/rDNA biomarker for the treatment of malaria. The market is likely to witness lucrative growth during the forecast period due to such discoveries and technological advancements.

There is a growing demand for biomarkers in clinical studies.  These are various types of disease-specific biomarkers, that provide more rapid and accurate disease diagnosis. This reduces the duration of clinical medicine trials and assists in speeding the medicine development process. Biomarker testing services are widely used in cancer medicine discovery as it identifies changes in a cell’s genetic material. Such advantages of biomarkers are expected to support the market's growth throughout the forecasted period.

Biomarker testing services are rapidly expanding because they can increase the production of novel and innovative medicines and biologic products needed to combat the pandemic. For instance, in March 2021, the FDA provided EUA for the Tiger Tech COVID Plus Monitor which is used to diagnose COVID-19 in asymptomatic individuals by using biomarkers; this also helps in the prevention of the disease. Similar initiatives by the regulatory authorities in the coming years are expected to support the market in the post-pandemic period.

Service Insights

The biomarker assay development & validation segment is anticipated to hold the highest market share of 59.8% in 2021 in the biomarker testing services market. Based on service, the market is segmented into biomarker assay development & validation, flow cytometry, and others. One of the key reasons supporting the segment's growth is the growing number of clinical research and drug discovery activities that require biomarker assay development and validation.

Biomarkers accounted for the FDA’s approval for 40.0% of personalized medicines in 2018; a high number of biomarker-based approvals promotes demand for biomarker assay development & validation. There is a growing demand for the companion diagnostics such as immunohistochemistry kits for testing biomarkers in cancer diseases. For instance, in August 2022, Roche received approval for its VENTANA MMR RxDx Panel IHC panel used to detect biomarkers in endometrial cancer patients. This further supports the demand for biomarker assay development.

The flow cytometry segment is expected to grow with a CAGR of 7.8% during the forecast period  Flow cytometry provides highly detailed information on any single cell in a heterogeneous population, and due to this reason, it is used in preclinical and clinical settings for generating biomarker data. Flow cytometry supports dose selection in clinical trials and is also suitable for patients who receive transplants. Technological advancements such as the launch of microfluidic flow cytometry for biomarker analysis are further improving biomarker testing. Thus supporting its demand in the market

End-User Insights

The Pharmaceutical and biotechnology companies segment held the largest share of 44.0% in 2021. The key end-user includes pharmaceutical and biotechnology companies, research institutes, and CROs.  An increase in the funding for clinical research by pharmaceutical and biotechnology is one of the key reasons supporting the segment growth. Moreover, there is a growing interest among pharmaceutical companies to develop targeted therapies for cancer. Owing to this in September 2022, AstraZeneca and Roche entered into a partnership to redefine the treatment and diagnosis of cancer in the Middle East and North Africa. The aim of the partnership was to remove barriers in biomarker testing and expand access to precision medicines in the region. 

Global biomarker testing services market share, by end-user, 2021 (%)

The CRO segment is expected to expand with a CAGR of 8.3% during the forecast period. Small and medium-sized CRO’s may lack biomarker testing service units, in order to avoid equipment costs and, reduce the expenses associated with hiring personnel intended for the biomarker testing used for medical research. CRO’s try to outsource biomarker testing to service providers. This is the key reason for supporting the market.

Regional Insights

In terms of the region, North America held the largest market share of 46.2% in 2021. The presence of key market players providing biomarker testing services in this region; a rise in disease burden that leads to an increase in laboratory diagnostic testing; the presence of advanced healthcare infrastructure; and growing R&D investment by the public organizations in the region are the factors supporting the market in the region.  For instance, in 2020, the Canadian government funded USD 78,000 to support research on COVID-19 biomarkers. The research was aimed at identifying biomarkers for COVID-19 severity detection.

Biomarker Testing Services Market Trends by Region

Asia Pacific is anticipated to witness the fastest growth of 7.2% CAGR during the forecast period. The growing demand for companion diagnostics in the region, followed by the increasing geriatric population is supporting demand for the biomarker testing services in the region. Moreover, initiatives by the government to promote clinical trials in the region are further supporting the market. For instance, in September 2019, the Ministry of Food and Drug Safety of South Korea announced a 5-year plan to improve clinical trials in South Korea. Such initiatives are expected to promote regional market growth.

Key Companies & Market Share Insights

The market is highly competitive and companies are adopting strategies such as regional expansions, product launches, partnerships and M&A deals to stay competitive in the market. For instance, in June 2022, Labcorp announced a collaboration with BML to expand its biomarker testing facilities in Japan. The partnership will help Labcorp strengthen its global presence. Some of the prominent players in the global biomarker testing services market include:

  • Bio Agilytix Labs

  •  Euro fins Scientific

  • SGS SA

  • Charles River Laboratories

  • Labcorp Drug Development

  • Thermo Fisher Scientific Inc.(PPD, Inc.)

  • ICON Plc


  • Syneos Health

  • Intertek Group Plc

Biomarker Testing Services Market Report Scope

Report Attribute


Market size value in 2022

USD 823.4 million

Revenue forecast in 2030

USD 1,399.4 million

Growth Rate

CAGR 6.9% from 2022 to 2030

Base year for estimation


Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors,  trends

Segments covered

Services, end user, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Netherlands; Sweden; Switzerland; China; India; Japan; Indonesia; Malaysia; Singapore; South Korea; Thailand; Taiwan; Australia; Brazil; Mexico; Argentina; Colombia; South Africa, Saudi Arabia; Israel; UAE

Report coverage

Revenue forecast, company share, competitive landscape, growth factors,  trends

Key companies profiled

BioAgilytix Labs, Euro fins Scientific, SGS SA, Charles River Laboratories, Labcorp Drug Development, Thermo Fisher Scientific Inc. (PPD, Inc.), ICON Plc, IQVIA, Syneos Health, and Intertek Group Plc

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Biomarker Testing Services Market Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 - 2030. For this study, Grand View Research has segmented the global biomarker testing services market based on the  services, end-user, and region:

Global Biomarker Testing Services Market Segmentation

  • Services Outlook (Revenue, USD Million, 2018 - 2030)

    • Biomarker Assay Development

    • Flow Cytometry

    • Others

  • End-user Outlook (Revenue, USD Million, 2018 - 2030)

    • Pharmaceutical and biotechnology companies

    • Research Institutes

    • CRO

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

      • Netherlands

      • Sweden

      • Switzerland

    • Asia Pacific

      • Japan

      • China

      • India

      • Indonesia

      • Malaysia

      • Singapore

      • South Korea

      • Thailand

      • Taiwan

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • Israel

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.